ErbB2 down-regulates microRNA-205 in breast cancer
- PMID: 21787752
- DOI: 10.1016/j.bbrc.2011.07.033
ErbB2 down-regulates microRNA-205 in breast cancer
Abstract
Gene amplification and protein overexpression of erbB2 (Her2/neu) has been observed in approximately 20-30% of breast cancers. ErbB2-positive breast cancer is tend to be more aggressive than other types of breast cancer and therefore further investigation on the signaling pathways of erbB2 is needed for the therapeutic target for breast cancer treatment. Here we report that microRNA-205 (miR-205), a molecule also reported to be associated with breast cancer, is negatively regulated by erbB2 overexpression. Breast epithelial cells exogenously overexpressed with erbB2 decreased the expression of miR-205, whereas increased the expression of cyclin D1, cyclin E, cyclin-dependent kinase 2 (CDK2), cyclin-dependent kinase 4 (CDK4), and cyclin-dependent kinase 6 (CDK6). The decreased expression of miR-205 slightly increased by the transfection of erbB2 siRNA into the erbB2-overexpressing breast cancer epithelial cells. Overexpression of erbB2 enabled breast epithelial cells to grow anchorage-independently in soft agar, and the transfection of the precursor of miR-205 into the cells leaded to the decrease in the ability to grow in soft agar. These results suggest that down-regulation of miR-205 in erbB2-overexpressing breast epithelial cells is essential for erbB2-induced tumorigenesis, and miR-205 may have the potential to be a novel important alternative therapeutic target for erbB2-positive breast cancer.
Copyright © 2011 Elsevier Inc. All rights reserved.
Similar articles
-
Premature senescence is a primary fail-safe mechanism of ERBB2-driven tumorigenesis in breast carcinoma cells.Cancer Res. 2005 Feb 1;65(3):840-9. Cancer Res. 2005. PMID: 15705882
-
C-erbB2, p27 and G1/S aberrations in human primary breast cancer.Anticancer Res. 2003 May-Jun;23(3A):2053-61. Anticancer Res. 2003. PMID: 12894578
-
Expression of c-erbB2, cyclin D1 and estrogen receptor and their clinical implications in the invasive ductal carcinoma of the breast.Jpn J Clin Oncol. 2007 Sep;37(9):708-14. doi: 10.1093/jjco/hym082. Jpn J Clin Oncol. 2007. PMID: 17940078
-
Cyclin e overexpression reduces infiltrative growth in breast cancer: yet another link between proliferation control and tumor invasion.Cell Cycle. 2006 Mar;5(6):606-9. doi: 10.4161/cc.5.6.2569. Epub 2006 Mar 15. Cell Cycle. 2006. PMID: 16582601 Review.
-
A human breast epithelial cell type with stem cell characteristics as target cells for carcinogenesis.Radiat Res. 2001 Jan;155(1 Pt 2):201-207. doi: 10.1667/0033-7587(2001)155[0201:ahbect]2.0.co;2. Radiat Res. 2001. PMID: 11121235 Review.
Cited by
-
Noncoding RNAs as novel biomarkers in prostate cancer.Biomed Res Int. 2014;2014:591703. doi: 10.1155/2014/591703. Epub 2014 Aug 28. Biomed Res Int. 2014. PMID: 25243154 Free PMC article. Review.
-
MicroRNA-205 directly regulates the tumor suppressor, interleukin-24, in human KB oral cancer cells.Mol Cells. 2013 Jan;35(1):17-24. doi: 10.1007/s10059-013-2154-7. Epub 2012 Dec 3. Mol Cells. 2013. PMID: 23212344 Free PMC article.
-
miR-29b, miR-205 and miR-221 enhance chemosensitivity to gemcitabine in HuH28 human cholangiocarcinoma cells.PLoS One. 2013 Oct 17;8(10):e77623. doi: 10.1371/journal.pone.0077623. eCollection 2013. PLoS One. 2013. PMID: 24147037 Free PMC article.
-
Advantages of Restoring miR-205-3p Expression for Better Prognosis of Gastric Cancer via Prevention of Epithelial-mesenchymal Transition.J Gastric Cancer. 2020 Jun;20(2):212-224. doi: 10.5230/jgc.2020.20.e19. Epub 2020 May 18. J Gastric Cancer. 2020. PMID: 32596004 Free PMC article.
-
Delivery of gene silencing agents for breast cancer therapy.Breast Cancer Res. 2013 May 8;15(3):205. doi: 10.1186/bcr3413. Breast Cancer Res. 2013. PMID: 23659575 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials
Miscellaneous